Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
AML
•
Hematology
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
Related Questions
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
For AML patients, when do you stop antiinfective agents?
Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
With the recent approval of quizartinib, what is your preferred first-line FLT3 inhibitor in combination with chemotherapy for a fit AML patient with a FLT3-ITD mutation?
What is the consensus on giving Pemivibart for Pre-Exposure COVID prophylaxis in immunocompromised patients?